Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H25IN4O8 |
| Molecular Weight | 560.3301 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CCN=C(Nc1ccc(cc1)I)O)C[C@@]([H])(C(=O)O)N=C(N[C@@]([H])(CCC(=O)O)C(=O)O)O
InChI
InChIKey=LFEGKCKGGNXWDV-NKNRFTOXSA-N
InChI=1S/C19H25IN4O8/c20-11-4-6-12(7-5-11)22-18(31)21-10-2-1-3-13(16(27)28)23-19(32)24-14(17(29)30)8-9-15(25)26/h4-7,13-14H,1-3,8-10H2,(H,25,26)(H,27,28)(H,29,30)(H2,21,22,31)(H2,23,24,32)/t13-,14-/m0/s1/i20-4
| Molecular Formula | C19H25IN4O8 |
| Molecular Weight | 560.3301 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
MIP-1095 I-123 is under investigation in clinical trial phase II to evaluate the safety and efficacy in combination with enzalutamide in patients with prostate-specific membrane antigen (PSMA)-avid metastatic castration-resistant prostate cancer who have progressed on abiraterone. It is known that MIP-1095 potently inhibited the glutamate carboxypeptidase activity of PSMA and when radiolabeled with 123I exhibited high affinity for prostate-specific membrane antigen (PSMA) on human prostate cancer LNCaP cells.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| (123)I-Labeled (S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl) ureido)pentyl)ureido)pentanedoic acid. | 2004 |
|
| Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. | 2009 Sep 1 |
|
| Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with (131)I-MIP-1095. | 2017 Jun |
Patents
Sample Use Guides
I-131-1095 will be administered intravenously at 100 mCi for the initial therapeutic dose, and up to 3 additional dose(s) between 75 mCi - 100 mCi each, administered at least 8 weeks apart as determined by initial dosimetry evaluation and occurrence of dose-limiting events.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 09:03:14 UTC 2021
by
admin
on
Sat Jun 26 09:03:14 UTC 2021
|
| Record UNII |
HD4940602J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB12994
Created by
admin on Sat Jun 26 09:03:14 UTC 2021 , Edited by admin on Sat Jun 26 09:03:14 UTC 2021
|
PRIMARY | |||
|
HD4940602J
Created by
admin on Sat Jun 26 09:03:14 UTC 2021 , Edited by admin on Sat Jun 26 09:03:14 UTC 2021
|
PRIMARY | |||
|
949575-25-1
Created by
admin on Sat Jun 26 09:03:14 UTC 2021 , Edited by admin on Sat Jun 26 09:03:14 UTC 2021
|
PRIMARY | |||
|
949575-25-1
Created by
admin on Sat Jun 26 09:03:14 UTC 2021 , Edited by admin on Sat Jun 26 09:03:14 UTC 2021
|
PRIMARY | |||
|
25168442
Created by
admin on Sat Jun 26 09:03:14 UTC 2021 , Edited by admin on Sat Jun 26 09:03:14 UTC 2021
|
PRIMARY |